CRIZANLIZUMAB
January 2022
NHP Guideline published
Following NICE recommendation of Crizanlizumab as a treatment option for preventing recurrent crises (vaso-occlusive crises, VOCs) in people aged 16 or over with sickle cell disease (SCD), the NHP has published this guideline in line with NICE Managed Access Agreement (MAA)
